Lasa Supergenerics (NSE:LASA) ROCE %: -31.10% (As of Mar. 2026)

What is Lasa Supergenerics ROCE %?

Lasa Supergenerics NSE:LASA -0.78% 46 ROCE % is -31.10% as of Mar. 2026. GuruFocus rates NSE:LASA with a GF Score™ of 46/100 and a GF Value™ of ₹4.36 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lasa Supergenerics's annualized ROCE % for the quarter that ended in Mar. 2026 was -31.10%.

Lasa Supergenerics (NSE:LASA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lasa Supergenerics ROCE % Related Terms

Lasa Supergenerics ROCE % Historical Data

* Premium members only.

The historical data trend for Lasa Supergenerics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lasa Supergenerics ROCE % Chart

Lasa Supergenerics Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

ROCE %

Get a 7-Day Free Trial

-3.69

-26.69

-15.40

-17.91

-51.12

Lasa Supergenerics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-104.34	-106.72	-39.83	-16.60	-31.10

46GF Score

Lasa Supergenerics Ltd NSE:LASA

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Lasa Supergenerics ROCE % Calculation

Lasa Supergenerics's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	-342.215	/	( ( (1015.32 - 171.545)	+	(662.718 - 167.724) )	/ 2 )
	=	-342.215	/	( (843.775	+	494.994)	/ 2 )
	=	-342.215	/	669.3845
	=	-51.12 %

Lasa Supergenerics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-153.928	/	( ( (0 - 0)	+	(662.718 - 167.724) )	/ 1 )
	=	-153.928	/	( ( 0	+	494.994 )	/ 1 )
	=	-153.928	/	494.994
	=	-31.10 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -31.10% mean?

Lasa Supergenerics (NSE:LASA) has a ROCE % of -31.10% as of Mar. 2026.

Is Lasa Supergenerics' ROCE % too high?

Lasa Supergenerics' current ROCE % is -31.10%. Overall, Lasa Supergenerics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Lasa Supergenerics' ROCE % compare to ZTS?

Lasa Supergenerics' ROCE % of -31.10% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lasa Supergenerics's current ROCE % is -31.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Lasa Supergenerics stock overvalued right now?

Based on GuruFocus' analysis, Lasa Supergenerics (NSE:LASA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹4.36, compared to a current price of ₹7.60 — trading 74.3% above its estimated fair value. The current ROCE % is -31.10%. Lasa Supergenerics' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Lasa Supergenerics (NSE:LASA), the current ROCE % is -31.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lasa Supergenerics (NSE:LASA) Overvalued in 2026?

Based on GuruFocus' analysis, Lasa Supergenerics stock appears to be overvalued. The current stock price of ₹7.60 is trading 74.3% above its estimated GF Value™ of ₹4.36. GuruFocus considers Lasa Supergenerics to be Significantly Overvalued.

Key valuation signals for NSE:LASA:

ROCE %: -31.10%
GF Value™: ₹4.36 vs. price of ₹7.60 (74.3% above fair value)
GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the NSE:LASA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lasa Supergenerics Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies BOM:524703 BOM:532637 BOM:540694 BOM:511523 BOM:539561 BOM:542248 NSE:JFLLIFE BOM:523620 BOM:524711 BOM:543963 XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges 540702:India

Address Plot No C-4, C-4/1, MIDC, Lote Parshuram Industrial Area, Khed Taluka, Ratnagiri, MH, IND, 415722

Website https://www.lasalabs.com

Lasa Supergenerics Ltd is engaged in the research, manufacturing, trading, producing, processing, preparing, and treating chemicals, API, pharmaceuticals, drugs, and related products. The company specializes in catalyst chemistry and manufactures anthelmintic and veterinary API products. Its product range includes API products, other API products, animal feed ingredients, and reagents for therapeutic use.

46GF Score

Get the complete analysis for NSE:LASA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹7.60

Price

₹4.36

GF Value

View NSE:LASA Analysis

See ROCE % data for all stocks →